Comparing Moderna (MRNA) & The Competition

Moderna (NASDAQ:MRNA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Moderna to similar companies based on the strength of its valuation, profitability, risk, earnings, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Moderna and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4	15	6	0	2.08
Moderna Competitors	9847	15133	45517	1589	2.54

Moderna presently has a consensus target price of $113.75, indicating a potential downside of 55.53%. As a group, “Biotechnology” companies have a potential upside of 102.75%. Given Moderna’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Moderna has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Moderna and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moderna	$1.94 billion	-$2.82 billion	-36.03
Moderna Competitors	$698.13 million	$10.43 million	-15.34

Moderna has higher revenue, but lower earnings than its rivals. Moderna is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Moderna and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Moderna Competitors	-12,359.35%	-203.09%	-30.93%

Risk and Volatility

Moderna has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Moderna’s rivals have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Institutional & Insider Ownership

75.3% of Moderna shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Moderna rivals beat Moderna on 7 of the 13 factors compared.

Moderna Company Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.